Comparison of Clinical Presentation and Prognosis Between Acral Cutaneous Melanoma and Non-Acral Cutaneous Melanoma.

Xieqiao Yan,Zhihong Chi,Xi Nan Sheng,Lu Si,Chuanliang Cui,Yan Kong,Bixia Tang,Li,Xuan Wang,Bin Lian,Jun Guo

DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.e20008

IF: 45.3

2015-01-01

Journal of Clinical Oncology

Abstract:e20008 Background: Acral cutaneous melanoma (ACM) is rare in Caucasian populations. Whether patients with ACM have a worse prognosis than patients with non-acral cutaneous melanoma (NACM) has not been determined. This observational study aimed to summarize the data in our center and compare the clinical features between ACM and NACM. Methods: A database was prospectively established for the purpose of this analysis. Medical record of all patients since 2006 were retrieved and reviewed. Statistical analyses were performed by SPSS 16.0. Results: Data were available for 658 cases (61.1%) of ACM and 419 cases (38.9%) of NACM. The proportions with clinical stage I, II, III, and IV diseases were 10.3%, 50.8%, 24.5% and 14.4% in ACM and 6.9%, 40.8%, 33.2%, 19.1% in NACM. The ACM cases included more male (56.4% vs 50.1%, P= 0.044) and ulceration (72.0% vs 58.5%, P= 0.000). The 5-year overall survival rate was 44.7% in ACM patients and 52.6% in NACM patients; the median survival time (OS) were 55.0 and 68.0 months respectively (P= 0.027). 5-y survival rates with stage I, II, III, and IV diseases were 89.1%, 53.8%, 24.5% , 8.0% and 96.8%, 63.2%, 35.2% and 9.6%, respectively. The median survival for stage I patients was not reached in both groups, Stage II: 65 vs 87.0 months (HR = 1.630, P= 0.023), Stage III: 30 vs 36 months (HR = 1.371, P= 0.043), Stage IV: 12 vs 13 months (HR = 1.466, P= 0.048). The median disease-free survival (DFS) was shorter in ACM (31 vs 37 months (HR = 1.213, P= 0.042) in all the patients; Stage I: not reached in the both group; Stage II: 35 vs 47 months (HR = 1.340, P= 0.015); Stage III: 14 vs 23 months (HR = 1.498, P= 0.000). Multivariate analysis revealed that the subtype of the disease (ACM vs NACM) was significant prognostic factors for OS (HR = 1.80, P= 0.000) and DFS (HR = 1.725, P= 0.004). Conclusions: ACM is the most commonly diagnosed subtype of cutaneous melanoma in Asia. As compared to NACM, more ACM were diagnosed at earlier stage, but with higher proportion of ulceration. The type of ACM was significantly associated with clinical outcome in terms of OS and DFS. Patients of ACM were more susceptible to recurrence, and associated with worse prognosis than patients with non-acral cutaneous melanoma.